President Donald Trump has unveiled the TrumpRx direct-to-consumer drug site, a government-backed platform aimed at lowering prescription drug costs for Americans willing to pay in cash rather than use insurance.
“You’re going to save a fortune and this is also so good for overall health care,” Trump said at the White House event announcing the site’s launch.
The TrumpRx direct-to-consumer drug site does not sell medicines directly. Instead, it acts as a central hub that redirects users to pharmaceutical companies offering discounted drugs through their own direct-to-consumer platforms or provides printable coupons redeemable at pharmacies.
At launch, TrumpRx lists medicines from five companies that recently struck pricing agreements with the administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. Additional manufacturers are expected to be added in the coming months, according to the White House.
The service is intended for use by cash-paying consumers. Patients who do not have insurance or who are underinsured will likely benefit the most. Patients with insurance will likely gain less benefit, as TrumpRx purchases will probably not apply to deductibles or out-of-pocket maximums.
“If they’re able to get a drug covered by their insurance at a relatively affordable copay, then there’s not a great upside to using the TrumpRx website,” said Juliette Cubanski, deputy director of the program on Medicare Policy at KFF.
Among the well-known drugs already listed on the site are Novo Nordisk GLP-1 medicines Ozempic and Wegovy and Eli Lilly’s weight-loss injection Zepbound. Prices advertised on TrumpRx can involve significant discounts off the list price, although analysts warn that figure may be far from what consumers actually save compared with negotiated insurer prices.
TrumpRx marks the official debut of Trump’s “most favored nation” drug pricing policy intended to link US prices to those in other wealthy nations. While some have praised the effort for potentially increasing access to some expensive drugs, others say it fails to meaningfully lower prices or help most Americans with health insurance.
